Prices are updated after-hours

Health Technology Autoimmunity

9 Meters Biopharma, Inc.

NMTR | $0.0722 -42.97% -67.9% 10M

(0.0% 1d) (0.0% 1m) (-93.6% 1y) (0.0% 2d) (0.0% 3d) (-43.0% 7d) (254.86% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 1,043,990
http://www.innovatebiopharma.com
Sec Filling | Patents | 8 employees

(US) 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

autoimmunity

add to watch list Paper trade email alert is off

ChemoCentryx, Inc.

CCXI | News | $51.99 -0.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees

(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

cancer autoimmunity

add to watch list Paper trade email alert is off

Applied Molecular Transport Inc.

AMTI 4 | $0.263 -14.3% -1.14% 0

Health Technology

(0.0% 1d) (0.0% 1m) (-8.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.46% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 10,871,516
http://www.appliedmt.com
Sec Filling | Patents | 80 employees

Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.

autoimmunity metabolic treatment

add to watch list Paper trade email alert is off

Compugen Ltd.

CGEN | $2.03 3.57% 3.45% 450K

Health Technology

(0.0% 1d) (-9.5% 1m) (275.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 181,152,054
http://www.cgen.com
Sec Filling | Patents | 61 employees

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

antibody autoimmunity monoclonal antibodies israel diagnostics

add to watch list Paper trade email alert is off

Concert Pharmaceuticals, Inc.

CNCE | $8.37 0.36% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.76% volume)
Earnings Calendar: 2023-03-02
Market Cap: $ 520,711,745
http://www.concertpharma.com
Sec Filling | Patents | 70 employees

(US) Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

autoimmunity nervous system molecule drugs

add to watch list Paper trade email alert is off

Rubius Therapeutics, Inc.

RUBY | $0.057 -99.3% 760K

Health Technology

(0.0% 1d) (0.0% 1m) (152.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-99.16% volume)
Earnings Calendar: 2023-05-09
Market Cap: $ 5,157,528
http://www.rubiustx.com
Sec Filling | Patents | 223 employees

(US) Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA.

cancer autoimmunity t-cell metabolic ceiling

add to watch list Paper trade email alert is off

Liminal BioSciences Inc.

LMNL | $8.5 0.12% 0.12% 0

Health Technology

(0.0% 1d) (0.0% 1m) (27.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-76.68% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 26,385,887
http://www.liminalbiosciences.com
Sec Filling | Patents | 300 employees

(CA) Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

cancer autoimmunity liver fibrosis lungs treatment kidney

add to watch list Paper trade email alert is off

TG Therapeutics, Inc.

TGTX | $14.25 1.06% 1.05% 3.2M

Health Technology

(0.0% 1d) (-10.1% 1m) (-37.7% 1y) (0.0% 2d) (0.0% 3d) (0.4% 7d) (-37.98% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 2,202,236,966
http://www.tgtherapeutics.com
Sec Filling | Patents | 134 employees

(US) TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

acquisitions autoimmunity t-cell treatment ceiling

Drugs

UKONIQ (umbralisib)

add to watch list Paper trade email alert is off

GENFIT S.A.

GNFT | $3.44 -6.01% -6.4% 2.2K

Health Technology

(0.0% 1d) (-0.4% 1m) (-1.9% 1y) (0.0% 2d) (0.0% 3d) (0.8% 7d) (351.77% volume)
Earnings Calendar:
Market Cap: $ 171,432,342
http://www.genfit.com
Sec Filling | Patents | 194 employees

(FR) Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

autoimmunity liver urea car-t drug discovery metabolic diagnostics treatment

add to watch list Paper trade email alert is off

Vaccinex, Inc.

VCNX | $4.94 -2.76% 7.4K

Health Technology

(0.0% 1d) (-36.3% 1m) (1155.1% 1y) (0.0% 2d) (0.0% 3d) (2.1% 7d) (-25.64% volume)
Earnings Calendar:
Market Cap: $ 6,084,114
http://www.vaccinex.com
Sec Filling | Patents | 49 employees

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

alzheimer huntington neurodegenerative neuroinflammatory cancer lung cancer antibody autoimmunity t-cell lungs treatment ceiling

add to watch list Paper trade email alert is off

Vertex Pharmaceuticals Incorporated

VRTX | $404.93 1.25% 1.43% 1.1M

Health Technology

(0.0% 1d) (-4.4% 1m) (19.4% 1y) (0.0% 2d) (0.0% 3d) (1.1% 7d) (NaN% volume)
Earnings Calendar: 2024-02-05
Market Cap: $ 104,657,941,761
http://www.vrtx.com
Sec Filling | Patents | 3000 employees

(US) Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

sclerosis cancer battery batteries autoimmunity infectious disease multiple sclerosis rheumatoid arthritis influenza fibrosis molecule drugs neurological treatment injection

Drugs

Kalydeco (ivacaftor)
ORKAMBI (lumacaftor and ivacaftor)
SYMDEKO (Tezacaftor and Ivacaftor)
Trikafta (Elexacaftor, Tezacaftor, and Ivacaftor)

add to watch list Paper trade email alert is off

Xencor, Inc.

XNCR | $18.35 0.77% 0.76% 480K

Health Technology

(0.0% 1d) (-16.8% 1m) (-35.8% 1y) (0.0% 2d) (0.0% 3d) (-4.5% 7d) (-38.58% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,121,556,991
http://www.xencor.com
Sec Filling | Patents | 166 employees

(United States) Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

cancer antibody autoimmunity monoclonal antibodies

add to watch list Paper trade email alert is off

Zai Lab Limited

ZLAB | $15.13 0.93% 0.93% 470K

Health Technology

(0.0% 1d) (-7.8% 1m) (-58.3% 1y) (0.0% 2d) (0.0% 3d) (9.3% 7d) (-2.26% volume)
Earnings Calendar:
Market Cap: $ 1,501,028,282
http://www.zailaboratory.com
Sec Filling | Patents | 692 employees

(China (Mainland)) Zai Lab Ltd. is a biopharmaceutical company. It engages in the discovering, licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need in the fields of oncology, infectious and autoimmune diseases. The company's products include Zejula and Optune. Zai Lab was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

china autoimmunity urea

add to watch list Paper trade email alert is off

AbbVie Inc.

ABBV | News | $169.54 0.98% -0.91% 4.1M

Health Technology

(0.0% 1d) (-6.0% 1m) (2.3% 1y) (0.0% 2d) (0.0% 3d) (2.4% 7d) (0.87% volume)
Earnings Calendar:
Market Cap: $ 300,195,489,498
http://www.abbvie.com
Sec Filling | Patents | 30000 employees

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

cancer hiv autoimmunity hepatitis fibrosis metabolic parkinson neurological

Drugs

Alcohol - Hand Sanitizer (Alcohol)
Androgel (Testosterone)
Creon (Pancrelipase)
Depakote (Divalproex Sodium)
Depakote ER (Divalproex Sodium)
Depakote Sprinkles (Divalproex Sodium)
Duopa (Carbidopa and Levodopa)
Gengraf (Cyclosporine)
Humira (Adalimumab)
Kaletra (Lopinavir and Ritonavir)
K-Tab (Potassium Chloride)
Lupaneta Pack (leuprolide acetate and norethindrone acetate)
Lupron Depot (leuprolide acetate)
Lupron Depot-PED (leuprolide acetate)
Marinol (Dronabinol)
Mavyret (Glecaprevir and Pibrentasvir)
Niaspan (Niacin)
Nimbex (Cisatracurium besylate)
Norvir (Ritonavir)
Oriahnn (Elagolix and Estradiol and Norethisterone)
Orilissa (Elagolix)
Rinvoq (Upadacitinib)
Skyrizi (Risankizumab-rzaa)
Survanta (Beractant)
Synthroid (Levothyroxine Sodium)
Tarka (Trandolapril and Verapamil Hydrochloride)
Tricor (Fenofibrate)
Trilipix (Fenofibric Acid)
Ultane (Sevoflurane)
Venclexta (Venetoclax)
Viekira Pak (Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir)
Zemplar (Paricalcitol)

add to watch list Paper trade email alert is off

Akari Therapeutics Plc

AKTX | $1.22 3.39% 3.28% 4.8K

Health Technology

(0.0% 1d) (-37.9% 1m) (570.5% 1y) (0.0% 2d) (0.0% 3d) (0.9% 7d) (272.17% volume)
Earnings Calendar:
Market Cap: $ 9,666,909
http://akaritx.com
Sec Filling | Patents | 10 employees

(US) Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

autoimmunity

add to watch list Paper trade email alert is off

ADiTx Therapeutics, Inc.

ADTX | $2.285 2.93% 2.84% 26K

Health Technology

(0.0% 1d) (-30.1% 1m) (207.1% 1y) (0.0% 2d) (0.0% 3d) (-7.9% 7d) (316.82% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 3,805,014
http://www.aditxt.com
Sec Filling | Patents | 2 employees

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

immunotherapy autoimmunity transplanted organs

add to watch list Paper trade email alert is off

Enlivex Therapeutics Ltd.

ENLV | News | $1.32 3.94% 3.79% 48K

Health Technology

(0.0% 1d) (-69.1% 1m) (-55.3% 1y) (0.0% 2d) (0.0% 3d) (-9.3% 7d) (-52.58% volume)
Earnings Calendar: 2022-11-18
Market Cap: $ 24,507,466
http://www.enlivex.com
Sec Filling | Patents | 77 employees

(IL) Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

sclerosis cancer autoimmunity israel multiple sclerosis car-t rheumatoid arthritis bone treatment cancer treatments

add to watch list Paper trade email alert is off

Alpine Immune Sciences, Inc.

ALPN | $64.535 -0.07% -0.07% 3.1M

Health Technology

(0.0% 1d) (72.0% 1m) (802.0% 1y) (0.0% 2d) (0.0% 3d) (0.2% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 4,230,019,887
http://www.alpineimmunesciences.com
Sec Filling | Patents | 53 employees

(US) Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The firm engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.

cancer immunotherapy autoimmunity

add to watch list Paper trade email alert is off

Apellis Pharmaceuticals, Inc.

APLS G | $48.69 2.2% 2.16% 1.2M

Health Technology

(0.0% 1d) (-14.2% 1m) (-46.3% 1y) (0.0% 2d) (0.0% 3d) (0.3% 7d) (NaN% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 5,871,125,359
http://www.apellis.com
Sec Filling | Patents | 235 employees

(United States) Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

immunotherapy autoimmunity treatment

add to watch list Paper trade email alert is off

argenx SE

ARGX | $375.13 1.73% 1.7% 340K

Health Technology

(0.0% 1d) (-7.4% 1m) (-5.7% 1y) (0.0% 2d) (0.0% 3d) (2.4% 7d) (1.27% volume)
Earnings Calendar:
Market Cap: $ 22,294,380,665
http://www.argen-x.com
Sec Filling | Patents | 188 employees

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

cancer antibody autoimmunity myeloid leukemia leukemia treatment

add to watch list Paper trade email alert is off